Perfil del autor: Bernabé-Caro, Reyes
Datos institucionales
| Nombre | Bernabé-Caro, Reyes |
| Departamento | Medicina |
| Área de conocimiento | Medicina |
| Categoría profesional | Profesora Asociada CIS |
| Correo electrónico | Solicitar |
 |
|
Estadísticas
-
Nº publicaciones
22
-
Nº visitas
998
-
Nº descargas
1046
| Publicaciones |
|---|
Tesis Doctoral
 Impacto de la pandemia por SARS-CoV-2 en pacientes con cáncer colorrectal en el área sanitaria del Hospital Universitario Virgen del Rocío y sus distritos de atención sanitaria
(2023)
Introducción: Desde la irrupción del SARS-CoV-2, la pandemia COVID ha tenido un gran impacto sobre el sistema sanitario, ... |
Artículo
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
(2023)
Background Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell ... |
Artículo
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
(Impact Journals, 2022)
This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 ... |
Artículo
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
(SPRINGER, 2022)
Introduction The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment ... |
Artículo
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
(BMC, 2022)
Background: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This ... |
Artículo
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
(ELSEVIER SCIENCE INC, 2022)
Introduction: In CheckMate 227, nivolumab plus ipilimu mab prolonged overall survival (OS) versus chemotherapy in patients ... |
Artículo
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective
(Taylor and Francis LTD, 2022)
Background: To assess the cost-effectiveness of using next-generation sequencing (NGS) compared to sequential single-testing ... |
Artículo
Impact of smoking status on the relative efficacy of the EGFR TKI/ angiogenesis inhibitor combination therapy in advanced NSCLCda systematic review and meta-analysis
(ESMO open, 2022)
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab ... |
Artículo
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
(AMER SOC CLINICAL ONCOLOGY, 2022)
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small cell lung cancer ... |
Artículo
Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
(MDPI, 2022)
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved ... |
Artículo
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
(SPRINGER, 2022)
Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic ... |
Artículo
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
(BMC, 2021)
Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. ... |
Artículo
Blood biomarkers associated to complete pathologicalresponse on NSCLC patients treated with neoadjuvantchemoimmunotherapy included in NADIM clinical trial
(Wiley Open Access, 2021)
Background:Immunotherapy is being tested in early-stage non-small cell lungcancer (NSCLC), and achieving higher rates of ... |
Artículo
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
(MDPI, 2021)
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond ... |
Artículo
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial
(Elsevier, 2021)
Background: To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced non small-cell ... |
Artículo
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial
(Wiley Open Access, 2021)
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from ... |
Artículo
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
(BMC, 2021)
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, ... |
Artículo
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
(2021)
Background: Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non small cell lung cancer ... |
Artículo
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
(American Society Clinical Oncology, 2021)
PURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III ... |
Artículo
Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy
(MDPI, 2020)
After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies ... |
Artículo
The roles of imprinted SLC22A18 and SLC22A18AS gene overexpression caused by promoter CPG island hypomethylation as diagnostic and prognostic biomarkers for non-small cell lung cancer patients
(MDPI, 2020)
Genomic imprinting is a process that involves one gene copy turned-off in a parent-of-origin-dependent manner. The regulation ... |
Artículo
Postnatal Fate of the Ultimobranchial Remnants in the Rat Thyroid Gland
(Wiley Periodicals, Inc., 2013)
The ultimobranchial follicles (UBFs) areconsidered embryonic remnants from the ultimobran-chial body (UBB). ... |